Technical Analysis for APTO - Aptose Biosciences, Inc.

Grade Last Price % Change Price Change
grade B 5.66 -5.67% -0.34
APTO closed down 5.67 percent on Monday, January 27, 2020, on 44 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down
Historical APTO trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Spinning Top Other 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -5.67%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.67%
Upper Bollinger Band Walk Strength -5.67%
Outside Day Range Expansion -5.67%
Upper Bollinger Band Touch Strength -5.67%
NR7 Range Contraction -9.15%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Aptose Biosciences Inc., a biopharmaceutical company, is engaged in the discovery, research, and development of novel anticancer therapies in Canada. The company's pipeline of cancer drug candidates includes small molecule therapies and immunotherapy. Its lead program, LOR-253, an anticancer agent, which has completed Phase I clinical trail for the treatment of solid tumors, as well as undergoing Phase II clinical trials for the treatment of relapsed/refractory hematologic malignancies. The company's discovery stage products include LOR-500, a MELK Inhibitor for Oncology, as well as small molecule programs. The company is also developing RNA-targeted therapies, including LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; and Virulizin, a novel immunotherapy agent that has completed three Phase I/II clinical studies in solid tumors and pancreatic cancers, as well as completed a randomized placebo-controlled Phase III clinical trial for the treatment of pancreatic cancer in combination with gemcitabine. In addition, its preclinical stage products comprise LOR-220, a novel small molecule for drug-resistant bacterial infections; and IL-17E1, an immuno-modulator for oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.
Medicine Biopharmaceutical Cancer Clinical Medicine Drugs Immunotherapy Oncology Solid Tumors Acute Myeloid Leukemia Pancreatic Cancer Targeted Therapy Bemcentinib Treatment Of Acute Myeloid Leukemia Phosphoinositide 3 Kinase Inhibitor Preclinical Stage Products Small Molecule Therapies Pancreatic Cancers Treatment Of Pancreatic Cancer

Is APTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.66
52 Week Low 1.57
Average Volume 1,360,722
200-Day Moving Average 2.79
50-Day Moving Average 4.36
20-Day Moving Average 5.74
10-Day Moving Average 5.92
Average True Range 0.47
ADX 50.02
+DI 26.05
-DI 19.33
Chandelier Exit (Long, 3 ATRs ) 5.24
Chandelier Exit (Short, 3 ATRs ) 6.46
Upper Bollinger Band 6.33
Lower Bollinger Band 5.15
Percent B (%b) 0.43
BandWidth 20.53
MACD Line 0.44
MACD Signal Line 0.52
MACD Histogram -0.0826
Fundamentals Value
Market Cap 136.01 Million
Num Shares 24 Million
EPS -0.78
Price-to-Earnings (P/E) Ratio -7.26
Price-to-Sales 0.00
Price-to-Book 2.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.43
Resistance 3 (R3) 6.40 6.12 6.30
Resistance 2 (R2) 6.12 5.93 6.13 6.25
Resistance 1 (R1) 5.89 5.80 6.01 5.92 6.21
Pivot Point 5.61 5.61 5.67 5.62 5.61
Support 1 (S1) 5.38 5.42 5.50 5.41 5.11
Support 2 (S2) 5.10 5.29 5.11 5.07
Support 3 (S3) 4.87 5.10 5.02
Support 4 (S4) 4.90